From GlobeNewswire: 2025-03-26 07:30:00

Mereo BioPharma Group plc announced financial results for 2024, highlighting progress in the Phase 3 study of setrusumab in osteogenesis imperfecta (OI). The Orbit study is moving towards the second interim analysis expected mid-2025, with potential regulatory approvals in the U.S. and EU. Alvelestat received Orphan Designation for AATD-LD.

Total R&D expenses for Mereo increased to $20.9 million in 2024, with higher expenses for alvelestat and setrusumab. General and administrative expenses also rose to $26.4 million. The net loss for 2024 was $43.3 million. Mereo’s cash balance stood at $69.8 million as of December 31, 2024, expected to fund operations into 2027.

Mereo BioPharma focuses on rare disease therapeutics, with setrusumab for OI and alvelestat for AATD-LD. The company’s partnership with Ultragenyx involves potential milestone payments and royalties. Financially, Mereo had $69.8 million in cash as of December 31, 2024, and expects to fund operations into 2027.

In 2024, Mereo reported a net loss of $43.3 million, with increased R&D and general administrative expenses. The company’s cash balance was $69.8 million as of December 31, 2024, enabling funding for clinical trials and operational expenses into 2027. Alvelestat and setrusumab are key rare disease product candidates for Mereo.



Read more at GlobeNewswire:: Mereo BioPharma Reports Full Year 2024 Financial Results